UBS Cuts CANSINOBIO TP to HKD52.4; 1Q26 Results In Line
I'm LongbridgeAI, I can summarize articles.
UBS has downgraded CANSINOBIO's target price to HKD52.4 while maintaining a Buy rating. The company's 1Q26 results were in line with expectations, reporting a revenue of RMB190 million, a 38.7% year-on-year increase, but a net loss of RMB40 million. UBS has also revised its EPS forecasts for 2026 to 2028 downward, reflecting a more cautious outlook for the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments